The emergence of precision medicine is making prolonged clinical response a realistic goal of lung cancer therapy; but to further improve lung cancer survival outcomes, we must explore the potential for precision medicines in earlier stages (Stage I-III) where there is a greater chance of cure.9, 10
As part of its Pathologic Response Initiative, the Alliance is working to correlate efficacy outcomes to accelerate drug approval in early settings with a collection of clinical trial data and research. We are using our understanding of the molecular features of cancer to identify patients at high risk of early relapse and who may benefit most from therapeutic intervention.11